Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2016, Pages

  Martí Carvajal, Arturo J ^a   Kwong, Joey S W ^b  

^a Iberoamerican Cochrane Network   (Venezuela)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PLACEBO; ROSUVASTATIN; CARBAZOLE DERIVATIVE; CARDIOTONIC AGENT; PROPANOLAMINE DERIVATIVE;

ADVERSE OUTCOME; CARDIOVASCULAR MORTALITY; CHAGAS DISEASE; CLINICAL FEATURE; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT FORM 36; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; CHAGAS CARDIOMYOPATHY; COMPLICATION; MIDDLE AGED; SURVIVAL ANALYSIS;

ADULT; CARBAZOLES; CARDIOTONIC AGENTS; CHAGAS CARDIOMYOPATHY; HEART FAILURE; HUMANS; MIDDLE AGED; PROPANOLAMINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROSUVASTATIN CALCIUM; SURVIVAL ANALYSIS;

EID: 84977652564     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009077.pub3     Document Type: Review

References (123)

1. Andrade MV, Boas FV, Daltro C, Carvalho C, Bernardes A, Nascimento T, et al. Effects of administration of short-term rosuvastatin in patients with heart failure due to Chagas disease etiology: A randomized, placebo-controlled trial. Cardiovascular Therapeutics 2012;30(Suppl 1):90.
2. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. American Heart Journal 2007;153(4):544.e1-8. [PUBMED: 17383291]
3. Diniz RVZ. Effect and tolerability of the carvedilol in chronic symptomatic Chagasic cardiomyopathy [Efeito e tolerabilidade do carvedilol no tratamento de miocardiopatia chagásica crônica sintomática: estudo duplo-cego, controlado com placebo [PhD Thesis]]. São Paulo, Brazil, Universidade Federal de São Paulo 2004. [419430 ]
4. Diniz RVZ, Viegas RFM, Amori JML, Pulz C, Carvalho ACDC, Almeida DR. [Impacto clínico da utilização do beta-bloqueador carvedilol na miocardiopatia chagásica crônica sintomática: estudo duplo-cego, randomizado, controlado com placebo]. Arquivos Brasileiros de Cardiologia. 2005; Vol. 84:66. [DOI: 10.1590/S0066-782X2005000100014]
5. Bestetti RB, Otaviano AP, Cardinalli-Neto A, da Rocha BF, Theodoropoulos TA, Cordeiro JA. Effects of B-Blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure. International Journal of Cardiology 2011;151:205-8. [PUBMED: 20591516]
6. Dávila DF, Angel F, Arata de Bellabarba G, Donis JH. Effects of metoprolol in chagasic patients with severe congestive heart failure. International Journal of Cardiology 2002;85(2-3):255-60. [MEDLINE: 12208592]
7. Dávila DF, Donis JH, Torres A, Gottberg CF, Ramoni-Perazzi P, Arata de Bellabarba G, et al. Beta-adrenergic blockers in chronic systolic heart failure secondary to Chagas' disease. International Journal of Cardiology 2008;128(1):1-4. [MEDLINE: 18378338]
8. Bocchi EA, Cruz F, Guimaraes G, Pinho Moreira LF, Issa VS, Ayub Ferreira SM, et al. Long-term prospective, randomized, controlled study using repetitive education at six-month intervals and monitoring for adherence in heart failure outpatients: the REMADHE trial. Circulation. Heart Failure 2008;1(2):115-24. [PUBMED: 19808281]
9. Issa VS, Amaral AF, Cruz FD, Ferreira SM, Guimaraes GV, Chizzola PR, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circulation. Heart Failure 2010;3(1):82-8. [PUBMED: 19933408]
10. Morillo CA. A randomized double-blind placebo force-titration controlled study with bisoprolol in patients with chronic heart failure secondary to Chagaś cardiomyopathy. https://clinicaltrials.gov/ct2/show/results/NCT00323973 (accessed 29 January 2016).
11. Abuhab A, Trindade E, Aulicino GB, Fujii S, Bocchi EA, Bacal F. Chagas' cardiomyopathy: the economic burden of an expensive and neglected disease. International Journal of Cardiology 2013;168:2375-80. [PUBMED: 23465560]
12. Acquatella H. Predicting heart failure and mortality in chronic Chagas' heart disease. A novel disorder in Spain. Revista Española de Cardiología 2008;61(2):105-7. [PUBMED: 18364176]
13. Adorisio R, De Luca L, Rossi J, Gheorghiade M. Pharmacological treatment of chronic heart failure. Heart Failure Reviews 2006;11(2):109-23. [PUBMED: 16937030]
14. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485. [PUBMED: 7647644]
15. Andrade JP, Marin-Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, et al. I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy [I Diretriz Latino-Americana para o Diagnostico e Tratamento da Cardiopatia Chagasica]. Arquivos Brasileiros de Cardiologia 2011;97(2 Suppl 3):1-48. [PUBMED: 21952638]
16. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
17. Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40. [PUBMED: 22511692]
18. Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. American Journal of Cardiovascular Drugs 2006;6(2):77-86. [PUBMED: 16555861]
19. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clinical Infectious Diseases 2009;49(5):e52-4. [PUBMED: 19640226]
20. Bestetti RB, Otaviano AP, Fantini JP, Cardinalli-Neto A, Nakazone MA, Nogueira PR. Prognosis of patients with chronic systolic heart failure: Chagas disease versus systemic arterial hypertension. International Journal of Cardiology 2013;168(3):2990-1. [PUBMED: 23642596]
21. Bestetti RB, Otaviano AP, Fantini JP, Cardinalli-Neto A, Nakazone MA, Nogueira PR. Mode of death in chronic systolic heart failure: Chagas cardiomyopathy versus systemic arterial hypertension. International Journal of Cardiology 2014;174(3):818-9. [PUBMED: 24794968]
22. Bimbi BJ, Unger P, Vandenbossche JL, Silance PG, Van Laethem Y. Chagas disease: don't forget it in Latin American patients with heart block!. Acta Cardiologica 2014;69(2):206-8. [PUBMED: 24783476]
23. Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy - where do we stand after a hundred years?. Progress in Cardiovascular Diseases 2010;52(4):300-16. [PUBMED: 20109600]
24. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many?. Current Molecular Medicine 2008;8(6):510-8. [PUBMED: 18781958 ]
25. Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011;66(5):588-95. [PUBMED: 21241318]
26. Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009-2010. Current Opinion in Infectious Diseases 2010;Sep 30:[Epub ahead of print]. [PUBMED: 20885320]
27. Carrasco HJ, Segovia M, Llewellyn MS, Morocoima A, Urdaneta-Morales S, Martinez C, et al. Geographical distribution of Trypanosoma cruzi genotypes in Venezuela. PLoS Neglected Tropical Diseases 2012;6(6):e1707. [PUBMED: 22745843]
28. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. [PUBMED: 23303884]
29. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7. [PUBMED: 23295957]
30. Costa J, Peterson AT. Ecological niche modelling as a tool for understanding distributions and interactions of vectors, hosts, and etiologic agents of Chagas disease. Advances in Experimental Medicine and Biology 2012;710:59-70. [PUBMED: 22127886]
31. Coura JR, Borges-Pereira J. Chagas disease: 100 years after its discovery. A systemic review. Acta Tropica 2010;115(1-2):5-13. [PUBMED: 20382097]
32. Cruz-Pacheco G, Esteva L, Vargas C. Control measures for Chagas disease. Mathematical Biosciences 2012;237(1-2):49-60. [PUBMED: 22450034]
33. Cunha-Neto E, Chevillard C. Chagas disease cardiomyopathy: Immunopathology and genetics. Mediators of Inflammation 2014;Epub Aug 19:11. [PUBMED: 25210230]
34. Diniz Lde F, Caldas IS, Guedes PM, Crepalde G, de Lana M, Carneiro CM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 2010;54(7):2979-86. [MEDLINE: 20404124]
35. Dobarro D, Gomez-Rubin C, Sanchez-Recalde A, Olias F, Bret-Zurita M, Cuesta-Lopez E, et al. Chagas' heart disease in Europe: an emergent disease?. Journal of Cardiovascular Medicine 2008;9(12):1263-7. [PUBMED: 19001935]
36. Dutra WO, Gollob KJ. Current concepts in immunoregulation and pathology of human Chagas disease. Current Opinion in Infectious Diseases 2008;21(3):287-92. [MEDLINE: 18448974]
37. Dávila DF, Rossell O, de Bellabarba GA. Pathogenesis of chronic Chagas heart disease: parasite persistence and autoimmune responses versus cardiac remodelling and neurohormonal activation. International Journal for Parasitology 2002;32(1):107-9. [MEDLINE: 11796128]
38. Dávila DF, Donis JH, Torres A, Ferrer JA. A modified and unifying neurogenic hypothesis can explain the natural history of chronic Chagas heart disease. International Journal of Cardiology 2004;96(2):191-5. [PUBMED: 15262032]
39. Dávila DF, Santiago JJ, Odreman WA. Vagal dysfunction and the pathogenesis of chronic Chagas disease. International Journal of Cardiology 2005;100(2):337-9. [PUBMED: 15823646]
40. Elias FE, Vigliano CA, Laguens RP, Levin MJ, Berek C. Analysis of the presence of Trypanosoma cruzi in the heart tissue of three patients with chronic Chagas' heart disease. The American Journal of Tropical Medicine and Hygiene 2003;68(2):242-7. [PUBMED: 12641419]
41. Esper L, Talvani A, Pimentel P, Teixeira MM, Machado FS. Molecular mechanisms of myocarditis caused by Trypanosoma cruzi. Current Opinion in Infectious Diseases 2015;28(3):246-52. [PUBMED: 25887609]
42. Fermi Paradox. crystalinks.com/fermiparadox.html (accessed 22 January 2015).
43. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. New England Journal of Medicine 1978;299:690-4. [PUBMED: 355881]
44. Gabriel SE, Normand SL. Getting the methods right - the Foundation of Patient-Centered Outcomes Research. New England Journal of Medicine 2012;367(9):787-90. [PUBMED: 22830434]
45. Gascón J, Albajar P, Cañas E, Flores M, Gómez i Prat J, Herrera RN, et al. Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic [Diagnóstico, manejo y tratamiento de la cardiopatíachagásica crónica en áreas donde la infección porTrypanosoma cruzi no es endémica]. Revista Española de Cardiología 2007;60(3):285-93. [PUBMED: 17394874]
46. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Tropica 2010;115(1-2):22-7. [PUBMED: 19646412]
47. Gironès N, Cuervo H, Fresno M. Trypanosoma cruzi-induced molecular mimicry and Chagas' disease. Current Topics in Microbiology and Immunology 2005;296:89-123. [PUBMED: 16323421]
48. Gironès N, Carrasco-Marin E, Cuervo H, Guerrero NA, Sanoja C, John S, et al. Role of Trypanosoma cruzi autoreactive T cells in the generation of cardiac pathology. Annals of the New York Academy of Sciences 2007;1107:434-44. [PUBMED: 17804572]
49. Granger BB, Ekman I, Granger CB, Ostergren J, Olofsson B, Michelson E, et al. Adherence to medication according to sex and age in the CHARM programme. European Journal of Heart Failure 2009;11(11):1092-8. [MEDLINE: 19875409]
50. Green SB. Design of randomized trials. Epidemiologic Reviews 2002;24:4-11. [PUBMED: 12119855]
51. Gurgel-Goncalves R, Galvao C, Costa J, Peterson AT. Geographic distribution of Chagas disease vectors in Brazil based on ecological niche modelling. Journal of Tropical Medicine 2012;2012:705326. [PUBMED: 22523500]
52. Guyatt G, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians. BMJ 2008;336:995-8. [PUBMED: 18456631]
53. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
54. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
55. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
56. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
57. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
58. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
59. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
60. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
61. Hamad E, Mather PJ, Srinivasan S, Rubin S, Whellan DJ, Feldman AM. Pharmacologic therapy of chronic heart failure. American Journal of Cardiovascular Drugs 2007;7(4):235-48. [PUBMED: 17696565]
62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60. [PUBMED: 12958120]
63. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
64. Higuchi ML, Benvenuti LA, Reis MM, Metzger M. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovascular Research 2003;60:96-107. [PUBMED: 14522411 ]
65. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. [PUBMED: 15545678]
66. Ioannidis JP. Perfect study, poor evidence: interpretation of biases preceding study design. Seminars in Hematology 2008;45(3):160-6. [PUBMED: 18582622]
67. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008;9(5):640-8. [PUBMED: 18633328]
68. Ioannidis JP. Meta-research: the art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
69. Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: A systematic review and pooled analysis. International Journal of Cardiology 2013;168(2):1186-94. [PUBMED: 23201083]
70. Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. The Medical Journal of Australia 2002;177:256-7. [PUBMED: 12197821]
71. Labathe DR. Chagas' disease and other cardiomyopathies. In: Labathe DR editor(s). Epidemiology and Prevention of Cardiovascular Diseases: A Global Challenge. 1st Edition. Maryland: Aspen, 1998:567-84. [ISBN 0-8342-0659-5]
72. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infectious Diseases 2013;13:342-8. [PUBMED: 23395248]
73. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
74. Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, et al. Chagas heart disease report on recent developments. Cardiology in Review 2012;20(2):53-65. [PUBMED: 22293860]
75. Malik LH, Singh GD, Amsterdam EA. The epidemiology, clinical manifestations, and management of Chagas heart disease. Clinical Cardiology 2015;38(9):565-9. [PUBMED: 25993972]
76. Malik LH, Singh GD, Amsterdam EA. Chagas Heart Disease: An update. The American Journal of Medicine 2015;128(11):1251.e7-9. [PUBMED: 26052027]
77. Marin-Neto JA, Bromberg-Marin G, Pazin-Filho A, Simoes MV, Maciel BC. Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas disease. International Journal of Cardiology 1998;65(3):261-9. [PUBMED: 9740483]
78. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115(9):1109-23. [MEDLINE: 17339569]
79. Medei EH, Nascimento JH, Pedrosa RC, Carvalho AC. Role of autoantibodies in the physiopathology of Chagas' disease. Arquivos Brasileiros de Cardiologia 2008;91(4):257-62, 281-6. [MEDLINE: 19009179]
80. Melton KD, Foil KJ, Yehle KS, Griggs RR. Heart failure in Hispanic Americans: Improving cultural awareness. The Journal for Nurse Practitioners 2015;11(2):207-13. [DOI: http://dx.doi.org/10.1016/j.nurpra.2014.08.010]
81. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. International Journal of Cardiology 2001;80(2):213-9. [PUBMED: 11578717]
82. Mills RM, Hobbs RE. Drug treatment of patients with decompensated heart failure. American Journal of Cardiovascular Drugs 2001;1(2):119-25. [PUBMED: 14728041]
83. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998;352:609-13. [PUBMED: 9746022]
84. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [PUBMED: 20332511]
85. Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Annals of Tropical Medicine and Parasitology 2006;100(8):663-77. [PUBMED: 17227647]
86. Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Memórias do Instituto Oswaldo Cruz 2009;104(Suppl 1):17-30. [PUBMED: 19753454]
87. Moncayo A. Carlos Chagas: biographical sketch. Acta Tropica 2010;115(1-2):1-4. [PUBMED: 19895782]
88. Muñoz J, Coll O, Juncosa T, Vergés M, del Pino M, Fumado V, et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clinical Infectious Diseases 2009;48(12):1736-40. [MEDLINE: 19438393]
89. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795-801. [MEDLINE: 15148066]
90. Olivieri BP, Molina JT, de Castro SL, Pereira MC, Calvet CM, Urbina JA, et al. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. International Journal of Antimicrobial Agents 2010;36(1):79-83. [PUBMED: 20452188]
91. Jannin J, Salvatella R. Quantitative estimation of Chagas Disease in the Americas [Estimación cuantitativa de la enfermedad de Chagas en Las Américas]. Organización Panamericana de la Salud. http://ops-uruguay.bvsalud.org 2006 (accessed 5 July 2016).
92. Pietri G, Van Ganse E, Ferrer M, Garin O, Wiklund I. MLHF. Minnesota living with heart failure questionnaire. User manual. 178.23.156.107:8085/Instruments_files/USERS/mlhf.pdf 2004 (accessed 27 January 2015).
93. Porta M. A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008.
94. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC. Clinical aspects of the Chagas' heart disease. International Journal of Cardiology 2007;115(3):279-83. [MEDLINE: 16769134]
95. Quiros FR, Morillo CA, Casas JP, Cubillos LA, Silva FA. CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]. Trials 2006;7:21. [PUBMED: 16764726]
96. Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007;115(9):1101-8. [PUBMED: 17339568]
97. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. New England Journal of Medicine 2006;355(8):799-808. [MEDLINE: 16928995]
98. Rassi Jr A, Rassi A, Marin-Neto JA. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Memórias do Instituto Oswaldo Cruz 2009;104(Suppl 1):152-8. [PUBMED: 19753470]
99. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375(9723):1388-402. [PUBMED: 20399979]
100. The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.
101. Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004102.pub2]
102. Ribeiro CH, López NC, Ramírez GA, Valck CE, Molina MC, Aguilar L, et al. Trypanosoma cruzi calreticulin: a possible role in Chagas' disease autoimmunity. Molecular Immunology 2009;46(6):1092-9. [PUBMED: 19108895]
103. Ribeiro Machado MP, Dias da Silva VJ. Autonomic neuroimmunomodulation in chagasic cardiomyopathy. Experimental Physiology 2012; Vol. 97, issue 11:1151-60. [PUBMED: 22581749]
104. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO. Diagnosis and management of Chagas disease and cardiomyopathy. Nature Reviews Cardiology 2012;9(10):576-89. [PUBMED: 22847166]
105. Rossi MA. The pattern of myocardial fibrosis in chronic Chagas' heart disease. International Journal of Cardiology 1991;30(3):335-40. [PUBMED: 2055674]
106. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Tropica 2010;115(1-2):14-21. [PUBMED: 19932071]
107. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [PUBMED: 7823387]
108. Silva CP, Del Carlo CH, Oliveira Junior MT, Scipioni A, Strunz-Cassaro C, Ramirez JA, et al. Why do patients with chagasic cardiomyopathy have worse outcomes than those with non-chagasic cardiomyopathy?. Arquivos Brasileiros de Cardiologia 2008;91(6):358-62. [PUBMED: 19142362]
109. Soriano Arandes A, Muñoz Gutierrez J, Vergés Navarro M, Castells Doménech C, Portús Vinyeta M, Gascón Brustenga J. Prevalence of Chagas disease in the Latin American immigrant population in a primary health centre in Barcelona (Spain). Acta Tropica 2009;112(2):228-30. [MEDLINE: 19631185]
110. Sousa GR, Costa HS, Souza AC, Nunes MCP, Lima MMO, Rocha MOD. Health-related quality of life in patients with Chagas disease: a review of the evidence. Revista Da Sociedade Brasileira De Medicina Tropical 2015;48:121-8. [25992924]
111. Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clinical Research in Cardiology 2014;103(1):1-10.
112. Tanowitz HB, Machado FS, Jelicks LA, Shirani J, de Carvalho AC, Spray DC, et al. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Progress in Cardiovascular Diseases 2009;51(6):524-39. [PUBMED: 19410685]
113. Teixeira AR, Hecht MM, Guimaro MC, Sousa AO, Nitz N. Pathogenesis of Chagas' disease: Parasite persistence and autoimmunity. Clinical Microbiology Reviews 2011;24(3):592-630. [PUBMED: 21734249]
114. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PloS one 2011;6(10):e25491. [PUBMED: 22028777]
115. Traina MI, Sanchez DR, Hernandez S, Bradfield JS, Labedi MR, Ngab TA, et al. Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles, California. Circulation-Heart Failure 2015;8(5):938-43. [PUBMED: 26206855]
116. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.MR000030.pub2]
117. Urbina J. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Tropica 2010;115(1-2):55-68. [PUBMED: 19900395]
118. Veloso HH. Incidence of sudden cardiac death in congestive heart failure: Chagas disease versus systemic arterial hypertension. International Journal of Cardiology 2014;175(1):175-6. [PUBMED: 24852839]
119. Villar JC, Villar LA, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003463]
120. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83. [PUBMED: 1593914]
121. Yamagata Y, Nakagawa J. Control of Chagas disease. Advances in Parasitology 2006;61:129-65. [PUBMED: 16735164]
122. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. The Journal of Infectious Diseases 1999;180(2):480-6. [PUBMED: 10395865 ]
123. Hidalgo R, Martí-Carvajal AJ, Kwong JSW, Simancas-Racines D, Nicola S. Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD009077.pub2]